{
    "nct_id": "NCT05204407",
    "official_title": "Luteolin for the Treatment of People With Schizophrenia",
    "inclusion_criteria": "* Either male or female of any race\n* Age is 18-60 years old\n* Meets DSM-5 criteria for schizophrenia or schizoaffective disorder\n* Positive and Negative Syndrome Scale (PANSS) total score of 75 or more OR a Clinical Global Impression severity of illness item score of 4 or more\n* Clinically stable\n* Treated with the same antipsychotic for at least 60 days and have received a constant therapeutic dose for at least 30 days prior to study entry\n* Able to participate in the informed consent process and provide voluntary informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Meets DSM-5 criteria for alcohol or substance misuse (except caffeine and nicotine) within the last 6 months; or a positive baseline urine drug screen. Participants who meet DSM-5 criteria for marijuana misuse - mild will be included in the study\n* A current infection, including HIV and Hepatitis C; or an organic brain disorder or medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol\n* Currently taking immunosuppressive medications (e.g. oral scheduled corticosteroids, chemotherapy or transplantation or HIV/AIDs associated drugs); or anti-inflammatory medications, including NSAIDs (e.g. ibuprofen, celecoxib, or naproxen) or aspirin > 81 mg on a daily basis. The use of PRN anti-inflammatory agents will be allowed.\n* Female participants who are pregnant or nursing",
    "miscellaneous_criteria": ""
}